Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Positioning therapies for the management of inflammatory bowel disease

Nature Reviews Gastroenterology & Hepatology volume 20, pages 411–412 (2023)Cite this article

Subjects

A careful integration of the effectiveness and safety of the therapies for inflammatory bowel disease, considering patients’ disease risks, treatment complications and preferences, is warranted to inform the positioning of therapies in clinical practice. Precision medicine might help choose the best option for an individual patient.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Proposed treatment algorithm for patients with moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis.

References

  1. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012).

    Article  CAS  PubMed  Google Scholar 

  2. Baumgart, D. C. & Le Berre, C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N. Engl. J. Med. 385, 1302–1315 (2021).

    Article  CAS  PubMed  Google Scholar 

  3. Singh, S. et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 6, 1002–1014 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Solitano, V. et al. Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 (2022).

    Article  PubMed  Google Scholar 

  5. Burr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976–1987 (2022).

    Article  CAS  Google Scholar 

  6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).

    Article  CAS  PubMed  Google Scholar 

  7. Biasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386–1395 (2019).

    Article  CAS  PubMed  Google Scholar 

  8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient’s disease course and whether they will respond to specific treatments? Gastroenterology 162, 1383–1395 (2022).

    Article  PubMed  Google Scholar 

  9. Sazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology 158, 189–199 (2020).

    Article  CAS  PubMed  Google Scholar 

  10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management of Crohn’s disease. Clin. Gastroenterol. Hepatol. 18, 1268–1279 (2020).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA

    Siddharth Singh

Authors
  1. Siddharth Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siddharth Singh.

Ethics declarations

Competing interests

S.S.’s institution has received research grants from Pfizer and AbbVie, and S.S. has received personal fees from Pfizer (for ad hoc grant review).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, S. Positioning therapies for the management of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 20, 411–412 (2023). https://doi.org/10.1038/s41575-023-00744-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-023-00744-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing